Coromandel International Limited Earnings Summary — Q1 FY2027
Coromandel International Reports Q1 Revenue Growth Driven by Nutrient Segment Expansion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 36.0% sequentially in Q1 FY2027.
- Revenue of ₹8,165 Cr is 15.9% higher year-on-year.
- Revenue has compounded at 38.7% annualised over the last 10 quarters.
- Net profit of ₹381 Cr is 24.6% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 46.9% annualised across the period.
- Operating margin stands at 9.3% in Q1 FY2027.
- Operating margin compressed by 185 bps year-on-year.
- Over the last two years operating margin has contracted by 111 bps.
- PBT margin is 6.3%.
- Expenses grew 18.4% against revenue growth of 15.9%.
- Operating profit of ₹756 Cr is 3.4% lower year-on-year.
- Operating leverage has been under pressure recently.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 61/100 (Healthy) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 8,165 | 6,004 | 8,779 | 9,654 | 7,042 | 4,988 | 6,935 | 7,433 | 4,729 | 3,913 |
| Expenses | Improving | 7,409 | 5,516 | 7,980 | 8,508 | 6,260 | 4,579 | 6,222 | 6,471 | 4,238 | 3,650 |
| Operating Profit | Volatile | 756 | 488 | 800 | 1,147 | 782 | 409 | 713 | 962 | 490 | 263 |
| Operating Margin | Improving | 9.3% | 8.1% | 9.1% | 11.9% | 11.1% | 8.2% | 10.3% | 12.9% | 10.4% | 6.7% |
| Other Income | Volatile | 50 | -6 | 83 | 116 | 84 | 473 | 114 | 65 | 54 | 84 |
| Interest | Improving | 89 | 89 | 84 | 102 | 68 | 66 | 73 | 66 | 57 | 62 |
| Depreciation | Strong Uptrend | 203 | 165 | 147 | 102 | 121 | 85 | 71 | 69 | 65 | 63 |
| Profit Before Tax | Volatile | 514 | 228 | 653 | 1,059 | 677 | 731 | 683 | 892 | 422 | 222 |
| Tax | Volatile | 132 | 113 | 164 | 266 | 176 | 152 | 175 | 233 | 113 | 58 |
| Net Profit | Volatile | 381 | 140 | 506 | 805 | 505 | 580 | 512 | 664 | 311 | 160 |
| Net Margin | Volatile | 4.7% | 2.3% | 5.8% | 8.3% | 7.2% | 11.6% | 7.4% | 8.9% | 6.6% | 4.1% |
Key Takeaways
- Consolidated revenue grew 15.9% YoY to ₹8,165 crore, led by a recovery in the Nutrient and other allied business segment.
- The Crop Protection segment showed strong performance, with revenue jumping to ₹1,250.76 crore from ₹724.85 crore in the prior year quarter, aided by the NACL acquisition.
- Bottom-line pressure remains as consolidated net profit fell 24% YoY, though it staged a significant recovery from the preceding quarter.
- The Board approved the conversion of a ₹108 crore loan into equity for its subsidiary, Coromandel Chemicals Limited.
- Restructuring of a $9.70 million loan for the Senegal-based step-down subsidiary BMCC was cleared to optimize capital structure.
- Nutrient segment results declined to ₹478.91 crore from ₹629.48 crore YoY, reflecting ongoing pricing and subsidy-related margin pressures.
- Strategic focus remains on backward integration and expanding the higher-margin Biologicals and Crop Protection segments.
Management Guidance
The company continues its transition from a subsidy-dependent fertilizer manufacturer to a diversified agri-solutions provider, targeting a 25% profit contribution from Crop Protection and Biologicals.
Sentiment Shift
Improving
While YoY profits are down, revenue growth is accelerating and margins are recovering from the lows seen in the fourth quarter of the previous fiscal year.
Outlook
The outlook remains positive for the Nutrient segment due to stable monsoons, while the Crop Protection segment is expected to benefit from the full-year integration of NACL and continued focus on biopesticide exports.
From the Annual Report (Key Quotes)
“The consolidated figures for the quarter ended 30 June 2026 may not be comparable with those for the quarter ended 30 June 2025 due to this acquisition [NACL].”
“The Board approved conversion of loan value amounting to about Rs. 108 Crores to equity shares... of Coromandel Chemicals Limited.”
“Approved the restructuring of loans amounting to USD 9.70 Million... into equity or preference shares.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Coromandel International Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.